Table II.
Change of diabetes parameters after dapagliflozin treatment.
| Parameters | Baseline | Week 20 | t/Z value | P-value |
|---|---|---|---|---|
| FPG, mmol/l | 11.5±0.6 | 7.0±0.3 | 8.429 | <0.001 |
| HbA1C, % | 8.8±0.3 | 7.2±0.2 | 6.492 | <0.001 |
| HOMA-β | 32.8±4.6 | 61.1±11.4 | 3.103 | 0.007 |
| HOMA-IR | 5.6±0.7 | 2.6±0.4 | 6.317 | <0.001 |
| TG, mmol/l | 1.75 (1.17-3.05) | 1.34 (0.94-1.79) | -4.361 | <0.001 |
| TC, mmol/l | 4.5±0.2 | 3.9±0.1 | 4.583 | <0.001 |
| LDL-C, mmol/l | 2.8±0.1 | 2.2±0.1 | 4.614 | <0.001 |
| HDL-C, mmol/l | 1.2±0.1 | 1.2±0.1 | 0.509 | 0.614 |
| Uric acid, µmol/l | 370.4±21.1 | 301.5±14.6 | 4.137 | <0.001 |
| hsCRP, mg/l | 9.6±3.4 | 3.5±0.9 | 2.180 | 0.043 |
| IL-6, pg/ml | 8.4±1.4 | 5.5±0.9 | 2.600 | 0.027 |
Data are presented as the mean ± SD, or median (lower quartile-upper quartile). FPG, fasting plasma glucose; HbA1C, glycated hemoglobin; HOMA-β, homeostatic model assessment of β-cell function; HOMA-IR, homeostasis model assessment-insulin resistance; TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin 6.